These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 30923630)
1. Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. Esfandiari NH; Rubenfire M; Neidert AH; Hench R; Eldin AJ; Meral R; Oral EA Clin Diabetes Endocrinol; 2019; 5():4. PubMed ID: 30923630 [TBL] [Abstract][Full Text] [Related]
3. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115 [TBL] [Abstract][Full Text] [Related]
4. New advances in the treatment of generalized lipodystrophy: role of metreleptin. Rodriguez AJ; Mastronardi CA; Paz-Filho GJ Ther Clin Risk Manag; 2015; 11():1391-400. PubMed ID: 26396524 [TBL] [Abstract][Full Text] [Related]
5. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin. Lebastchi J; Ajluni N; Neidert A; Oral EA J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101 [TBL] [Abstract][Full Text] [Related]
6. Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report. Nagayama A; Ashida K; Moritaka K; Hidaka M; Gobaru M; Tanaka S; Hasuzawa N; Akasu S; Goto Y; Motomura S; Hara K; Tsuruta M; Wada N; Nakayama H; Tajiri Y; Nomura M J Endocr Soc; 2019 Nov; 3(11):2179-2183. PubMed ID: 31720553 [TBL] [Abstract][Full Text] [Related]
7. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649 [TBL] [Abstract][Full Text] [Related]
8. A Novel Subtype of Acquired Generalized Lipodystrophy Associated With Subcutaneous Panniculitis-Like T-cell Lymphoma. Hoff FW; Xing C; Garg A JCEM Case Rep; 2024 May; 2(5):luae069. PubMed ID: 38681964 [TBL] [Abstract][Full Text] [Related]
9. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy. Nagayama A; Ashida K; Watanabe M; Moritaka K; Sonezaki A; Kitajima Y; Takahashi H; Yoshinobu S; Iwata S; Yasuda J; Hasuzawa N; Ozono S; Motomura S; Nomura M Front Endocrinol (Lausanne); 2021; 12():690996. PubMed ID: 34135866 [TBL] [Abstract][Full Text] [Related]
10. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. Diker-Cohen T; Cochran E; Gorden P; Brown RJ J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254 [TBL] [Abstract][Full Text] [Related]
11. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Misra A; Garg A Medicine (Baltimore); 2003 Mar; 82(2):129-46. PubMed ID: 12640189 [TBL] [Abstract][Full Text] [Related]
12. Influence of diet and body weight in treatment-resistant acquired partial lipodystrophy after hematopoietic stem cell transplantation and its potential for metabolic improvement. Ishida E; Horiguchi K; Matsumoto S; Ozawa A; Sekiguchi S; Yamada E Diabetol Int; 2024 Apr; 15(2):290-296. PubMed ID: 38524924 [TBL] [Abstract][Full Text] [Related]
14. Metreleptin worked in a diabetic woman with a history of hematopoietic stem cell transplantation (HSCT) during infancy: further support for the concept of 'HSCT-associated lipodystrophy'. Adachi M; Muroya K; Hanakawa J; Asakura Y Endocr J; 2021 Apr; 68(4):399-407. PubMed ID: 33229817 [TBL] [Abstract][Full Text] [Related]
15. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis. Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100 [TBL] [Abstract][Full Text] [Related]
16. Metreleptin Treatment in Three Patients with Generalized Lipodystrophy. Musso C; Major ML; Andres E; Simha V Clin Med Insights Case Rep; 2016; 9():123-127. PubMed ID: 28096701 [TBL] [Abstract][Full Text] [Related]
17. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy. Miehle K; Stumvoll M; Fasshauer M; Hierl T Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984 [TBL] [Abstract][Full Text] [Related]
18. Rationale for leptin-replacement therapy for severe lipodystrophy. Oral EA; Chan JL Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299 [TBL] [Abstract][Full Text] [Related]
19. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161 [TBL] [Abstract][Full Text] [Related]
20. Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution. Adiyaman SC; V Schnurbein J; De Laffolie J; Hahn A; Siebert R; Wabitsch M; Kamrath C J Pediatr Endocrinol Metab; 2022 Jul; 35(7):946-952. PubMed ID: 35405042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]